Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Esketamine Coverage Update | OpenP…
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy MP 5.01.34

    Esketamine Nasal Spray for Depression

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.34 alerts

    Get alerted when Policy MP 5.01.34 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-necessity and prior-authorization criteria for esketamine nasal spray in adults with treatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior, including FDA-label-consistent use and Spravato REMS compliance.

    Policy Summary
    PayerBluecross Idaho
    PolicyEsketamine Nasal Spray for Depression
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateFeb 1, 2026
    Last ReviewOct 30, 2025
    Next Review DateN/A
    Key ActionDocument two inadequate antidepressant trials from different classes, including adequate duration and at least 80% adherence, before requesting treatment-resistant depression authorization.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was updated to include use of esketamine nasal spray as monotherapy for treatment-resistant depression.

    18+Minimum age
    2Prior antidepressant trials
    MADRS ≥28 or HAMD ≥17Depression severity threshold
    28 daysInitial authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 year
    Maximum reauthorization
    InvestigationalOutside criteria

    Medical Necessity and Coverage Criteria

    Initial therapy for treatment-resistant depression

    Esketamine nasal spray may be considered medically necessary when ALL of the following are met.

    Initial therapy for treatment-resistant depression: Individual is 18 years of age or older; meets DSM-5 criteria for a major depressive episode by structured clinical interview; has a current moderate or severe depressive episode; has tried and had an inadequate response to two antidepressants from two different classes with adequate duration and adherence; does not have a current substance use disorder unless in remission with complete abstinence for one month; has no FDA-labeled contraindication and will use esketamine consistently with the FDA-approved label and Spravato REMS; and the prescriber is a specialist or has consulted a specialist.Age ≥18; MADRS ≥28 OR HAMD ≥17; two antidepressants from different classes; each trial at least 6 weeks or physician-determined sufficient duration; adherence ≥80%

    Initial authorization is for 28 days.

    Continuation therapy

    Esketamine nasal spray may be reauthorized for up to 1 year when ALL of the following are met.

    Reauthorization for treatment-resistant depression: Individual has improvement in depression symptoms assessed with an appropriate depression rating scale; does not have a current substance use disorder; and has not developed an FDA-labeled contraindication while treatment remains consistent with the FDA-approved label and Spravato REMS requirements.Reauthorization period up to 1 year

    Examples of acceptable rating scales include PHQ-9, CUDOS, QIDS-SR-16, MADRS, and HAM-D.

    Acute suicidal ideation or behavior

    Esketamine nasal spray with an oral antidepressant may be considered medically necessary for 28 days when ALL of the following are met.

    Major depressive disorder with acute suicidal ideation or behavior: Individual is 18 years of age or older; meets DSM-5 criteria for a major depressive episode by structured clinical interview; has a current moderate or severe depressive episode; is currently hospitalized and at imminent risk of suicide; has a structured-assessment response indicating imminent risk and confirmation by a mental health professional or psychiatrist; receives esketamine with standard-of-care treatment; has no FDA-labeled contraindication and will use esketamine consistently with the FDA-approved label and Spravato REMS; and the prescriber is a specialist or has consulted a specialist.Age ≥18; MADRS ≥28 OR HAMD ≥17; 28-day treatment period

    Standard-of-care treatment may include oral antidepressants, an atypical antipsychotic, or a mood stabilizer. Use beyond 4 weeks has not been systematically evaluated.

    Not covered or investigational situations

    Esketamine is investigational in all other situations.

    Investigational use: Use does not meet the specified criteria for treatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior.None

    Such use is considered investigational.

    Esketamine nasal spray is contraindicated for individuals with aneurysmal vascular disease, including disease of the thoracic or abdominal aorta or intracranial or peripheral arteries; an arteriovenous malformation; an intracerebral hemorrhage; or hypersensitivity to esketamine, ketamine, or any excipient. These contraindications must be absent for coverage.

    Esketamine nasal spray is considered investigational when the request does not meet the specified criteria for treatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior. Coverage is therefore limited to the policy-defined indications and requirements, including applicable diagnostic, severity, treatment, safety, supervision, and Spravato REMS criteria.

    Coding and Clinical Thresholds

    CPTCPT
    J0013Esketamine, nasal spray, 1 mg.
    HCPCSHCPCS
    N/A.
    ICD-10-CMICD-10
    F32.0-F32.3Major Depressive disorder, single episode, moderate to severe.
    F32.89Other specified depressive episodes.
    F32.9Major depressive disorder, single episode, unspecified.
    F33.0-F33.3Major depressive disorder, recurrent, moderate to severe.
    F33.8Other recurrent depressive disorders.
    ICD-10-PCSICD-10
    F33.9Major depressive disorder, recurrent, unspecified.
    MADRS threshold
    Coverage thresholdMADRS score ≥28
    Severity indicatedModerate or severe current depressive episode
    Applicable useInitial treatment-resistant depression or acute suicidal ideation/behavior authorization
    HAMD threshold
    Coverage thresholdHAMD score ≥17
    Severity indicatedModerate or severe current depressive episode

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization: Treatment-Resistant Depression

    Initial authorization for esketamine nasal spray may be approved for 28 days when the individual meets the treatment-resistant depression criteria and all safety, labeling, and specialist-prescriber requirements are documented.

    • Age 18 or older.
    • DSM-5 major depressive episode established by a structured clinical interview.
    • Current episode is moderate or severe, with MADRS ≥28 or HAMD ≥17.
    • No current substance use disorder unless in remission with complete abstinence for at least 1 month.
    • No FDA-labeled contraindication; treatment must follow the FDA-approved label and Spravato REMS requirements.
    • Prescriber is a specialist in the diagnosis, such as a psychiatrist, or has consulted with one.
    Prior Authorization

    Reauthorization: Up to 1 Year

    Reauthorization is available for up to 1 year when continued treatment is supported by documented clinical improvement and the individual continues to meet substance-use, contraindication, labeling, and REMS requirements.

    Policy Background

    This policy addresses esketamine nasal spray for adults with moderate or severe major depressive episodes in two settings: treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior. Treatment-resistant depression requires inadequate response to two antidepressants from different classes, while the acute suicidal ideation or behavior indication requires use with standard-of-care treatment during a 28-day period. Treatment must be provided under direct healthcare-provider supervision in a medically supervised setting that complies with the Spravato REMS program because of risks including sedation, dissociation, abuse, and misuse.

    Clinical Definitions and Abbreviations

    Adequate antidepressant trial
    Minimum durationAt least 6 weeks at generally accepted doses
    AlternativeA sufficient duration determined by the treating physician at generally accepted doses
    AdherenceAt least 80% adherence during the trial
    MADRS
    Structure10-item depression-severity scale
    Score rangeTotal score ranges from 0 to 60
    Severity bands20–34 indicates moderate depression; 35–60 indicates severe depression

    Level of Care Criteria

    Covered Treatment Modalities

    Esketamine nasal spray treatment modality

    Covered treatment must meet ALL of the following administration and monitoring requirements.

    Esketamine nasal spray treatment: Treatment is provided under direct healthcare-provider supervision in a medically supervised, REMS-compliant setting; blood pressure is assessed before and after treatment; the individual is monitored for at least 2 hours and assessed for clinical stability before leaving; and treatment follows the FDA-approved label.At least 2 hours of monitoring per session

    For treatment-resistant depression, induction is twice weekly during weeks 1-4, followed by weekly dosing during weeks 5-8 and weekly or every-2-week dosing from week 9 onward. For acute suicidal ideation or behavior, the recommended dose is 84 mg twice weekly for 4 weeks, reducible to 56 mg twice weekly for tolerability.

    Esketamine nasal spray treatment modality

    ALL of the following apply to the treatment setting.

    Administration setting:

    Authorization Periods and Treatment Limits

    Initial authorization or acute suicidal ideation treatment
    Initial authorization28 days
    Covered indicationsTreatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior
    Acute suicidal ideation treatmentEsketamine is used with an oral antidepressant for the 28-day treatment period
    Treatment-resistant depression reauthorization
    Reauthorization periodUp to 1 year
    Applicable indicationTreatment-resistant depression
    Requirement
    Policy Summary
    PayerBluecross Idaho
    PolicyEsketamine Nasal Spray for Depression
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateFeb 1, 2026
    Last ReviewOct 30, 2025
    Next Review DateN/A
    Key ActionDocument two inadequate antidepressant trials from different classes, including adequate duration and at least 80% adherence, before requesting treatment-resistant depression authorization.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Clinical ThresholdsAuthorization and Documentation RequirementsPolicy BackgroundClinical Definitions and AbbreviationsLevel of Care CriteriaCovered Treatment ModalitiesAuthorization Periods and Treatment Limits
    Applicable use
    Initial treatment-resistant depression or acute suicidal ideation/behavior authorization
    Antidepressant adherence
    Required adherenceAt least 80% during each antidepressant trial
    Applies toEach adequate antidepressant trial
    Related requirementTrial must also meet the required duration at generally accepted doses
    Antidepressant trial duration
    Minimum durationAt least 6 weeks at generally accepted doses
    Alternative durationSufficient duration determined by the treating physician at generally accepted doses
    Applies toEach adequate antidepressant trial
    Substance-use remission
    Required remission statusComplete abstinence for 1 month
    Applies whenThe individual has a substance use disorder in remission
    Current disorderA current substance use disorder does not meet the treatment-resistant depression criterion
    Post-treatment monitoring
    Monitoring durationAt least 2 hours at each treatment session
    Before leavingClinical stability must be assessed
    SettingTreatment is administered under direct healthcare-provider supervision
    Prior antidepressant treatment
    Number of attemptsTwo antidepressant treatment attempts
    Drug classesThe two agents must be from two different antidepressant classes
    Response requiredEach attempt must have resulted in an inadequate response
    Typical adequate treatment duration
    Typical minimum durationAt least 4 weeks
    Applies toAn antidepressant treatment attempt considered adequate in commonly used definitions
    Evidence limitationExperts do not agree on a single adequate dose or duration
    Major depressive episode duration
    Required symptomsFive or more symptoms
    DurationSymptoms persist for 2 weeks
    Required core symptomAt least one symptom is depressed mood or anhedonia
    HAM-D remission
    Remission thresholdHAM-D total score ≤7
    ScalePhysician-scored depression measure
    InterpretationLower scores indicate less depression
    HAM-D treatment response
    Response threshold50% reduction from baseline HAM-D score
    MeasureChange is assessed from the baseline score
    ScaleHAM-D measures depression severity
    MADRS remission
    Remission thresholdMADRS total score ≤7
    ScalePhysician-scored measure of depression severity
    InterpretationLower scores indicate less depression
    MADRS treatment response
    Response threshold50% reduction from baseline MADRS score
    MeasureChange is assessed from the baseline score
    ScaleMADRS measures the presence and severity of depression
    SUSTAIN-1 stable remission
    Stable remissionMADRS total score ≤12
    Required periodFor at least 3 of the last 4 weeks
    StudySUSTAIN-1
    SUSTAIN-1 stable response
    Stable responseMADRS total score reduction ≥50%
    Required periodFor the last 2 weeks of optimization
    Additional conditionThe individual must not meet remission criteria
    Relapse definition
    MADRS criterionTotal score ≥22 for 2 consecutive weeks
    Other criterionHospitalization for worsening depression
    Additional criterionAnother clinically relevant event indicative of relapse
    • Document improvement in depressive symptoms using an appropriate rating scale, such as PHQ-9, CUDOS, QIDS-SR16, MADRS, or HAM-D.
    • Individual does not have a current substance use disorder.
    • No FDA-labeled contraindication has developed; treatment continues according to the FDA-approved label and Spravato REMS requirements.
    Prior Authorization

    Initial Authorization: Acute Suicidal Ideation or Behavior

    Esketamine nasal spray, used with an oral antidepressant, may be authorized for a 28-day treatment period for adults with major depressive disorder and acute suicidal ideation or behavior when imminent suicide risk and all clinical requirements are documented.

    • Individual is 18 years of age or older and meets DSM-5 criteria for a major depressive episode by structured clinical interview.
    • Current episode is moderate or severe, with MADRS ≥28 or HAMD ≥17.
    • Individual is currently hospitalized and at imminent risk of suicide, supported by a structured suicidal-ideation assessment and confirmation by a mental health professional or psychiatrist.
    • Treatment is provided with standard-of-care therapy based on clinical judgment and practice guidelines, which may include oral antidepressants, an atypical antipsychotic, or a mood stabilizer.
    • No FDA-labeled contraindication; treatment follows the FDA-approved label and Spravato REMS requirements.
    • Prescriber is a diagnosis specialist or has consulted with one.
    Documentation Required

    Administration and Monitoring Requirements

    Each esketamine treatment session must be administered and monitored in accordance with the FDA label and safety requirements. The provider must document supervision, blood-pressure assessments, pre-treatment counseling, and observation through clinical stability before discharge.

    • Administer under the direct supervision of a healthcare provider in a medically supervised healthcare setting.
    • Assess blood pressure before and after treatment.
    • Advise the individual to avoid food for at least 2 hours and liquids for at least 30 minutes before administration.
    • Advise avoidance of nasal corticosteroids or nasal decongestants for 1 hour before treatment.
    • Monitor for at least 2 hours after each session and assess clinical stability before discharge.
    • For treatment-resistant depression: administer twice weekly during weeks 1–4, once weekly during weeks 5–8, and once weekly or every 2 weeks from week 9 onward, using the least frequent effective schedule.
    • For acute suicidal ideation or behavior: administer 84 mg twice weekly for 4 weeks; reduce to 56 mg twice weekly based on tolerability. Use beyond 4 weeks has not been systematically evaluated.
    Step Therapy

    Two Antidepressant Trials Required

    For treatment-resistant depression, document inadequate response to two antidepressant agents from two different classes. Each trial must meet the policy definition of an adequate trial unless the treating physician documents a sufficient duration at generally accepted doses.

    • Eligible classes include SSRIs, SNRIs, tricyclic antidepressants, bupropion, and mirtazapine.
    • Each trial lasted at least 6 weeks at generally accepted doses, or a sufficient duration as determined by the treating physician at generally accepted doses.
    • Individual adherence was at least 80% during each trial.
    • Document the agents, classes, doses, trial duration, adherence, response, and reason each trial was considered inadequate.
    Documentation Required

    Treatment-Resistant Depression Documentation

    The medical record must establish the diagnosis, severity, prior treatment history, and clinical qualifications supporting treatment-resistant depression before initial authorization is requested.

    • Document age and DSM-5 major depressive episode based on a structured clinical interview.
    • Record current severity using MADRS ≥28 or HAMD ≥17.
    • Document the two failed or inadequately effective antidepressant trials from different classes, including duration and adherence.
    • Document substance-use status, FDA contraindication screening, FDA-label use, and specialist involvement or consultation.

    Unsupported block type: documentation

    Documentation Required

    Acute Suicide-Risk Documentation

    For authorization based on acute suicidal ideation or behavior, the record must demonstrate current imminent risk rather than only a history of suicidal thoughts or behavior.

    • Document current hospitalization and imminent suicide risk.
    • Record the individual's response to a structured suicidal-ideation assessment; relevant tools may include the Mini-International Neuropsychiatric Interview, Beck Scale for Suicide Ideation, or Columbia-Suicide Severity Rating Scale.
    • Document confirmation of imminent risk by a mental health professional or psychiatrist.
    • Include the assessment date, findings, clinical judgment, and the standard-of-care treatment provided with esketamine.
    Documentation Required

    Reauthorization Documentation

    Requests for reauthorization must show that the individual benefited from treatment and continues to meet all ongoing safety and program requirements.

    • Submit an appropriate depression rating scale demonstrating improvement in depressive symptoms.
    • Document the current absence of a substance use disorder.
    • Reassess and document FDA-labeled contraindications, FDA-label adherence, and Spravato REMS compliance.
    Denial Risk

    Noncovered Indications

    Esketamine nasal spray is considered investigational when used outside the covered treatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior indications described in the policy.

    • Use for situations not meeting the policy's covered indications is investigational.
    Denial Risk

    Denial Risk: Medical Necessity and Safety

    Authorization may be denied when medical-necessity, treatment, prescriber, labeling, or safety requirements are not met or cannot be documented.

    • Individual is younger than 18 years of age.
    • DSM-5 major depressive episode, required severity, structured interview, or applicable acute-risk documentation is absent.
    • Required antidepressant trials, different drug classes, adequate duration, or ≥80% adherence are not documented for treatment-resistant depression.
    • Current substance use disorder is present, unless the policy exception for remission with at least 1 month of complete abstinence applies.
    • An FDA-labeled contraindication is present, or treatment is not consistent with the FDA-approved label.
    • Specialist involvement or consultation is not documented.
    • Spravato REMS enrollment, certified setting, supervised administration, monitoring, or required safety documentation is absent.
    • For acute suicidal ideation or behavior, the individual is not hospitalized or imminent suicide risk is not established by structured assessment and clinical confirmation.
    Denial Risk

    Denial Risk: Reauthorization

    Reauthorization may be denied when continued clinical benefit or ongoing eligibility cannot be demonstrated for the requested period.

    • No documented improvement in depressive symptoms on an appropriate rating scale.
    • Current substance use disorder is present.
    • A new FDA-labeled contraindication has developed.
    • Treatment is not being provided consistently with the FDA-approved label or Spravato REMS requirements.
    HAMD
    Structure17-item depression-severity rating scale
    Score rangeTotal score ranges from 0 to 52
    Severity bands17–23 indicates moderate depression; ≥24 indicates severe depression
    Spravato REMS
    Program typeRestricted safety program for esketamine nasal spray
    AdministrationRequires medically supervised administration and monitoring
    Program featuresCertified pharmacies and healthcare settings, patient counseling, and enrollment of all individuals in a registry
    Treatment-resistant depression
    DefinitionFailure of 2 or more antidepressant treatment attempts
    Treatment adequacyAttempts must have adequate dose and duration
    Diagnostic contextMay occur in major depressive disorder or bipolar disorder depressive episodes
    Major depressive disorder
    Diagnostic basisMeeting DSM-5 diagnostic criteria for major depressive disorder
    Psychotic featuresDefined here without psychotic features
    Policy contextRelevant to the population addressed by the esketamine policy
    Current suicidal ideation with intent
    Required responseYes to MINI Question B3 regarding current thoughts of self-harm or suicide with at least some intent or awareness of possible death
    Intent responseYes to MINI Question B10 regarding intent to act on thoughts of killing oneself
    TimingB3 must refer to the present; B10 may reflect the preceding 24 hours
    Major depressive episode
    SymptomsFive or more symptoms, including depressed mood or anhedonia
    DurationSymptoms occur for 2 weeks
    ExclusionsThe episode is not attributable to a substance or medical condition, better explained by psychotic illness, or preceded by a manic or hypomanic episode
    MADRS in the evidence discussion
    MeasurePhysician-scored 10-item measure of the presence and severity of depression
    Item scoringItems are scored from 0 to 6
    InterpretationHigher scores indicate more severe depression; trial remission thresholds have ranged from 6 to 12
    HAM-D in the evidence discussion
    MeasurePhysician-scored depression measure
    VersionsAvailable in 17- or 25-item versions; the 17-item version is more common
    ScoringScores range from 0 to 48, with higher scores indicating greater depression
    SIBAT
    Assessment typePatient- and clinician-reported assessment
    Suicidality modulesIncludes severity of suicidality and imminent suicide risk
    Additional moduleAssesses frequency of suicidal thinking
    MADRS abbreviation and scoring
    Full nameMontgomery-Asberg Depression Rating Scale
    Scoring usePhysician-scored measure of the presence and severity of depression
    Common versionThe commonly used version has 17 items and scores from 0 to 48
    Remission and response
    RemissionTotal MADRS score of 7 or less
    Response50% reduction from baseline MADRS scores
    UseDefinitions are provided in the evidence discussion
    SIBAT abbreviation
    Full nameSuicide Ideation and Behavior Assessment Tool
    Reporter typesContains patient- and clinician-reported modules
    Assessment areasSeverity of suicidality, imminent suicide risk, and frequency of suicidal thinking
    CGI-SR-I
    Full nameClinical Global Impression of Imminent Suicide Risk Scale
    Scale rangeRates imminent suicide risk from 0 to 6
    Endpoints0 indicates no imminent suicide risk; 6 indicates extreme imminent risk
    AD
    AbbreviationAD
    Full termAntidepressant
    Use in policyRefers to antidepressant treatment or therapy
    DSM
    AbbreviationDSM
    Full termDiagnostic and Statistical Manual of Mental Disorders
    Diagnostic useDSM-5 criteria are used to establish a major depressive episode or major depressive disorder
    CGI-S
    AbbreviationCGI-S
    Full termClinical Global Impression-Severity
    Measure typeClinical global impression severity measure
    IDS-C30
    AbbreviationIDS-C30
    Full termInventory of Depressive Symptomatology-Clinician
    Measure typeClinician-administered depressive symptom inventory
    MADRS
    AbbreviationMADRS
    Full termMontgomery-Asberg Depression Rating Scale
    Measure typeDepression-severity rating scale
    MGH-ATRQ
    AbbreviationMGH-ATRQ
    Full termMassachusetts General Hospital-Antidepressant Treatment Response Questionnaire
    Measure typeAntidepressant treatment-response questionnaire
    SIBAT
    AbbreviationSIBAT
    Full termSuicide Ideation and Behavior Assessment Tool
    Assessment typeTool used to assess suicidal ideation and behavior
    RCT
    AbbreviationRCT
    Full termRandomized controlled trial
    Study typeControlled clinical trial design used in the evidence review
    Study abbreviations
    DBDouble-blind
    NCTNational clinical trial
    MADRS; RCT; SIBATMontgomery-Asberg Depression Rating Scale; randomized controlled trial; Suicide Ideation and Behavior Assessment Tool
    Evidence abbreviations
    CGI-SS-rClinical Global Impression-Severity of Suicidality-revised
    CIConfidence interval
    LS; MADRSLeast-squares; Montgomery-Asberg Depression Rating Scale
    Esketamine nasal spray is administered in a medically supervised setting because of the risk of sedation and dissociation.

    Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior

    The following describes the evaluated treatment population and regimen.

    ASPIRE acute suicidal ideation/behavior trial population: Adults with moderate-to-severe major depressive disorder, MADRS total score greater than 28, active suicidal ideation and intent, and treatment with esketamine 84 mg or placebo nasal spray twice weekly for 4 weeks; a one-time reduction to 56 mg was allowed for intolerance. All participants received inpatient psychiatric hospitalization and a newly initiated or optimized oral antidepressant as standard care.MADRS >28; twice weekly for 4 weeks

    This describes the study population and intervention, not a policy coverage requirement.

    Esketamine nasal spray monotherapy for treatment-resistant depression

    The following summarizes the reviewed evidence.

    Monotherapy treatment-resistant depression trial: A phase 4 randomized trial evaluated esketamine nasal spray monotherapy in patients with treatment-resistant depression. Esketamine 56 mg or 84 mg was administered twice weekly for 4 weeks, with improvement in MADRS scores compared with placebo at day 28; a subsequent 12-week open-label phase evaluated continued esketamine or standard-care oral antidepressant treatment.Twice weekly for 4 weeks

    This describes clinical evidence and is not a policy coverage requirement.

    Esketamine with oral antidepressant

    The following summarizes the reviewed evidence.

    Treatment-resistant depression with oral antidepressant: Evidence reviewed for esketamine used in conjunction with an oral antidepressant; four randomized controlled trials evaluated this treatment approach.

    Esketamine monotherapy

    The following summarizes the reviewed evidence.

    Monotherapy in treatment-resistant depression: Evidence reviewed for esketamine monotherapy in treatment-resistant depression; one 4-week randomized controlled trial with an 8-week open-label extension supported labeling expansion.

    Esketamine with oral antidepressant for acute suicidal ideation or behavior

    The following summarizes the reviewed evidence.

    Major depressive disorder with acute suicidal ideation or behavior: Evidence reviewed for adults with moderate-to-severe major depressive disorder and active suicidal ideation or intent receiving esketamine in conjunction with an oral antidepressant.
    Depression symptoms must improve on an appropriate rating scale and other reauthorization criteria must be met